This company listing is no longer active
73C Stock Overview
Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Concert Pharmaceuticals, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$7.82 |
52 Week High | US$7.89 |
52 Week Low | US$2.44 |
Beta | 0.52 |
1 Month Change | 2.60% |
3 Month Change | 83.35% |
1 Year Change | 207.80% |
3 Year Change | -6.93% |
5 Year Change | -58.53% |
Change since IPO | -22.69% |
Recent News & Updates
Recent updates
Shareholder Returns
73C | DE Biotechs | DE Market | |
---|---|---|---|
7D | -0.4% | -1.2% | -0.8% |
1Y | 207.8% | -15.8% | 1.0% |
Return vs Industry: 73C exceeded the German Biotechs industry which returned 8.3% over the past year.
Return vs Market: 73C exceeded the German Market which returned 2.5% over the past year.
Price Volatility
73C volatility | |
---|---|
73C Average Weekly Movement | 9.0% |
Biotechs Industry Average Movement | 4.9% |
Market Average Movement | 4.9% |
10% most volatile stocks in DE Market | 9.9% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 73C's share price has been volatile over the past 3 months.
Volatility Over Time: 73C's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2006 | 64 | Roger Tung | www.concertpharma.com |
Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases. The company’s lead product candidate is CTP-543, which is in Phase III clinical trial for the treatment of alopecia areata, a serious autoimmune dermatological condition. It has strategic collaborations with Avanir Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Cipla Technologies; and Processa Pharmaceuticals.
Concert Pharmaceuticals, Inc. Fundamentals Summary
73C fundamental statistics | |
---|---|
Market cap | €487.33m |
Earnings (TTM) | -€118.56m |
Revenue (TTM) | €29.99m |
16.3x
P/S Ratio-4.1x
P/E RatioIs 73C overvalued?
See Fair Value and valuation analysisEarnings & Revenue
73C income statement (TTM) | |
---|---|
Revenue | US$32.04m |
Cost of Revenue | US$102.70m |
Gross Profit | -US$70.66m |
Other Expenses | US$56.02m |
Earnings | -US$126.68m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
Earnings per share (EPS) | -2.04 |
Gross Margin | -220.53% |
Net Profit Margin | -395.36% |
Debt/Equity Ratio | 0% |
How did 73C perform over the long term?
See historical performance and comparison